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Background: Studies have demonstrated an association of the BRAFV600E mutation and microRNA (miR)
expression with aggressive clinicopathologic features in papillary thyroid cancer (PTC). Analysis of BRAFV600E
mutations with miR expression data may improve perioperative decision making for patients with PTC, spe-
cifically in identifying patients harboring central lymph node metastases (CLNM).
Methods: Between January 2012 and June 2013, 237 consecutive patients underwent total thyroidectomy and
prophylactic central lymph node dissection (CLND) at four endocrine surgery centers. All tumors were tested
for the presence of the BRAFV600E mutation and miR-21, miR-146b-3p, miR-146b-5p, miR-204, miR-221, miR-
222, and miR-375 expression. Bivariate and multivariable analyses were performed to examine associations
between molecular markers and aggressive clinicopathologic features of PTC.
Results: Multivariable logistic regression analysis of all clinicopathologic features found miR-146b-3p and
miR-146b-5p to be independent predictors of CLNM, while the presence of BRAFV600E almost reached sig-
nificance. Multivariable logistic regression analysis limited to only predictors available preoperatively (mo-
lecular markers, age, sex, and tumor size) found miR-146b-3p, miR-146b-5p, miR-222, and BRAFV600E
mutation to predict CLNM independently. While BRAFV600E was found to be associated with CLNM (48%
mutated in node-positive cases vs. 28% mutated in node-negative cases), its positive and negative predictive
values (48% and 72%, respectively) limit its clinical utility as a stand-alone marker. In the subgroup analysis
focusing on only classical variant of PTC cases (CVPTC), undergoing prophylactic lymph node dissection,
multivariable logistic regression analysis found only miR-146b-5p and miR-222 to be independent predictors of
CLNM, while BRAFV600E was not significantly associated with CLNM.
Conclusion: In the patients undergoing prophylactic CLNDs, miR-146b-3p, miR-146b-5p, and miR-222 were found
to be predictive ofCLNMpreoperatively.However, therewas significant overlap in expression of thesemiRs in the two
outcome groups. The BRAFV600E mutation, while being a marker of CLNM when considering only preoperative
variables among all histological subtypes, is likely not a useful stand-alone marker clinically because the difference
between node-positive and node-negative cases was small. Furthermore, it lost significance when examining only
CVPTC.Overall, our results speak to the concept and interpretation of statistical significance versus actual applicability
of molecular markers, raising questions about their clinical usefulness as individual prognostic markers.
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Introduction
The incidence of thyroid cancer worldwide has risensignificantly in the last decade and papillary thyroid
cancer (PTC) is the most prevalent histological type, com-
prising approximately 80% of reported cases (1,2). Overall,
the majority of patients have an excellent clinical outcome
when treated with appropriate surgical and medical therapy
(3). However, 5–10% experience a more aggressive clinical
course, characterized by recurrent disease and early metas-
tases, resistance to radioactive iodine, and increased mor-
tality (3,4). Thyroidectomy and therapeutic neck dissection is
recommended for patients with known metastatic lymph
nodes identified either pre- or intraoperatively (3). However,
the benefit of prophylactic central lymph node dissection
(CLND) in patients who have no pre- or intraoperative evi-
dence of nodal metastasis remains controversial (3,5,6).
Some argue that CLND may reduce the recurrence rate of
lymph node metastasis, while others claim that patients re-
ceive no benefit, yet experience increased risk of permanent
hypoparathyroidism and recurrent laryngeal nerve injury (6–
8). Furthermore, currently available preoperative features
have not accurately identified PTCs that are associated with
lymph node metastases (LNM) (9), making it difficult to
tailor the extent of surgery (3) and specifically whether to
perform a prophylactic CLND (10).
The BRAFV600E mutation is the most common genetic
mutation in PTC (11,12). The p.BRAFV600E mutation is
caused by a c.1799 T>A transversion that results in a
constitutively activated mitogen-activated protein kinase
(MAPK) pathway, leading to tumorigenesis (13) and dis-
tinct biological consequences (14). The prevalence of the
BRAFV600Emutation varies between the different histological
subtypes of PTC (12). The tall-cell variant of PTC (TCVPTC)
has the highest prevalence at 93% (15), followed by classical
variant of PTC (CVPTC), comprising up to 75.3% (11), and
lastly, follicular variant of PTC (FVPTC) at only 25% (16).
Some studies have shown that the BRAFV600E mutation is
associated with aggressive clinicopathologic features, such as
extrathyroidal invasion, multifocality, lymphovascular inva-
sion, large tumor size, local lymph node metastasis, distant
metastasis, and advanced disease stages (17–22), whereas
others studies have demonstrated no association between the
BRAFV600E mutation and aggressive features (23–30). In a
previous retrospective study, the BRAFV600E mutation was
found to be an independent predictor of CLNM in the overall
cohort of patients with PTC (23). However, this relationship
lost significance when only CVPTC was included in the
analysis (23). Despite the discrepancies that exist in the lit-
erature, some studies have suggested the incorporation of
BRAFV600E mutation into the management algorithm of PTC
to improve perioperative decision making (9,17,18,20,22).
However, the usefulness of BRAFV600E in predicting the
presence of LNM remains questionable (23,31).
The recent expansion of knowledge and the ongoing effort
to characterize PTCs genetically by The Cancer Genome
Atlas (TCGA) research thyroid working group have also
suggested that micro-RNAs may influence the PTC pheno-
type and thereby play an important role in its prognosis (12).
MicroRNAs (miRs) are small non-protein coding RNA
molecules that are 21–25 nucleotides in length. They regulate
gene expression at the post-transcriptional level by binding to
imperfectly complementary sequences within target mRNAs,
often in the 3¢-untranslated regions, thereby leading to deg-
radation or translational suppression (32). Although defini-
tive studies are currently lacking, miRs may nevertheless
have potential as prognostic indicators in PTC, thereby op-
timizing the surgical management of patients with PTC
(28,33–44).
The BRAFV600E mutation and miRs have the potential to
guide surgical decision making. However, most previous
studies were retrospective, and did not include patients who
had undergone routine CLND, challenging the validity of the
findings. This underscores the need for well-designed pro-
spective studies involving routine CLND to investigate
whether the BRAFV600Emutation and miRs are independent
predictors of aggressive clinicopathologic features before
it can be recommended that these molecular markers be
incorporated into the management algorithm for patients
with PTC.
Accordingly, a multi-institutional prospective study was
carried out that included consecutive patients who underwent
total thyroidectomy (TT) and routine CLND at four tertiary
endocrine surgery centers between January 1, 2012, and June
30, 2013. The objective was to determine, by multivariable
analysis, whether the BRAFV600E mutation and miR expres-
sion levels of seven selected miRs are associated with ag-
gressive clinicopathologic features of PTC. Their association
with CLNM was examined in the subset of patients under-
going prophylactic rather than therapeutic CLND, in order to
explore their potential future value as factors to assist in
guiding the treatment of patients with PTC, specifically
whether to perform prophylactic CLND in the absence of
clinically apparent LNM.
Material and Methods
Patients and data collection
Under Institutional Review Board approval and patient
consent, a prospective multi-institutional study was con-
ducted that included Johns Hopkins Hospital, Weill Cornell
Medical Center, the University of Michigan Health Systems,
and theMayo Clinic. This study was designed as validation of
an initial retrospective pilot study (23). Consecutive patients
between January 1, 2012, and June 30, 2013, diagnosed with
PTC preoperatively on cytopathology or intraoperatively on
frozen section and with a tumor size ‡1 cm were prospec-
tively enrolled and included. Patients were operated on by
surgeons who routinely perform TT and prophylactic CLND
for patients with PTC ‡1 cm. At all centers, a unilateral
CLND was performed, as described by Carty et al. (45),
unless there was evidence of positive disease midline or
contra-laterally in which case bilateral dissection was per-
formed. Patients with suspicious or cytologically positive
lymph node metastasis detected on ultrasound or by in-
traoperative evaluation underwent therapeutic CLND and
were excluded, whereas those patients that did not exhibit
signs of lymphadenopathy either pre- or intraoperatively, by
definition, underwent a prophylactic CLND.
Clinical variables examined included patient age, sex, his-
tory of radiation exposure, and family history of thyroid cancer.
Surgical pathology reports were reviewed for the following:
tumor size, PTC subtype, presence LNM, extrathyroidal ex-
tension (ETE), multifocality, lymphovascular invasion (LVI),
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involvement of surgical margins, and American Joint Com-
mittee on Cancer (AJCC) stage.
Nucleic acid extraction
All molecular analyses were performed at Johns Hopkins
Hospital. DNA and total RNA were extracted from formalin-
fixed paraffin-embedded (FFPE) tumor samples, according to
the protocol outlined by Kotorashvili et al. (46). Final DNA
and RNA quantitation was determined by absorbance and
fluorescence spectroscopy–based nucleic acid quantification
using NanoDrop 2000c UV-Vis Spectrophotometer (Thermo
Scientific) and Qubit Fluorometric Quantitation (Life
Technologies). PTC subtype and follicular and tall-cell ar-
chitecture percentage was reviewed and confirmed by a sin-
gle head and neck/endocrine pathologist ( J.A.B.). Tumors
were classified as FVPTC if they were 99% follicular pat-
terned, and as TCVPTC if they had ‡50% tall-cell features.
BRAFV600E mutation detection
Detection of the BRAFV600E mutation was performed in all
cases by pyrosequencing. Polymerase chain reaction (PCR)
amplification of a 124-base region of BRAF exon 15 sur-
rounding c.1799T was performed using 20–200ng genomic
DNA and 0.2M 5¢-GAAGACCTCACAGTAAAAATAG-
3¢ (forward) and 5¢-biotin-ATA GCC TCA ATT CTT ACC
ATC C-3¢ (reverse) primers, along with HotStarTaq DNA
polymerase (Qiagen), according to the manufacturer’s in-
structions. Thermocycling parameters were as follows: 95C
for 15min, followed by 42 cycles of 95C for 20 sec, 53C for
50 sec, 72C for 20 sec, followed by 72C for 5min. Pyr-
osequencing was performed using the Pyromark-24 and se-
quencing reagents (Qiagen), according to the manufacturer’s
instructions, with the sequencing primer 5¢-GAC CTC ACA
GTA AAA ATA GGT GAT TTT G-3¢. The pyrosequencing
assay used was designed to detect all reported COSMIC (cat-
alog of somatic mutations in cancer; http://cancer.sanger
.ac.uk/cosmic/) mutations from 596 to 605, including K601E,
K601I, K601L, K601N, K601Q, and K601R mutations. Sam-
ples with low pyrosequencing signals were classified as in-
determinate and re-amplified using 52 cycles. Positive,
negative, and no-template controls were run with each sample.
BRAFV600E mutations (c.1799T>A, GTG>GAG) were diag-
nosed as positive based on the appearance of an A in the
chromatogram and a decrease of the wild-type T peak with a
mutant peak cutoff of 5%. This cutoff was based on testing of
normal colon and normal thyroid FFPE samples, which dis-
played percentages in the range 0–3%. More complex results
were resolved using a combination of Sanger sequencing and
Pyromaker software (23,47). The CLIA-approved laboratory
in which the pyrosequencing was performed has run large se-
ries of validation experiments against both Sanger sequencing
and next-generation sequencing (NGS) protocols, with 100%
agreement among all three methods. In addition, postoperative
molecular analysis for BRAFV600E mutation is known to be
accurate, with several studies documenting concordance of
molecular analysis in FNA and corresponding tumors (48,49).
miR analysis
Promising miR candidates for predicting aggressiveness
were selected based on results from the TCGA thyroid study
(12) and a recent systematic review of the literature (50).
MiRs-21, -146-3p, -146-5p, -204, -221, -222, and -375 were
measured along with candidate reference miR-16 in technical
triplicates. Reverse transcription for each specific miR was
performed using 2 lL (10 ng/lL) of total RNA for a total RT-
PCR reaction of 12lL. For the qPCR step, cDNAwas diluted
with 20 lL of water, and 2 lL of diluted cDNA added to
10 lL of master mix for total volume of 12 lL per qPCR
reaction (TaqMan MicroRNA Reverse Transcription kit,
TaqMan Universal Master Mix II, not containing Uracil-N
glycosylase [UNG], and TaqMan MicroRNA assays; Life
Technologies). MicroRNA TaqMan assays and their part
numbers from Life Technologies were: miR-21-5p (000397),
miR-146b-5p (001097), miR-146b-3p (002361), miR-204
(000508), miR-221 (000524), miR-222 (002276), miR-375
(000564), and miR-16-5p (000391).
In order to minimize batch effects, samples from all con-
tributing centers were randomized on the microtiter plates.
Mean Ct values were calculated for each sample and nor-
malized against miR-16 to obtain dCT values. MiR-16-5p
was used as endogenous control to normalize miR expression
levels based on prior publications (43,51–55) as well as
available TCGA thyroid data, where miR-16 appears as rel-
atively invariant within thyroid tumor samples (12). Mean
dCt values relative to expression of miR-16 were normally
distributed in the data set.
Data analysis
Power calculation. The study sample size was calculated
based upon the proportional prevalence of BRAFV600E mu-
tations and the prevalence of lymph node metastases in pa-
tients treated for PTC reported in previous studies. The
BRAFV600Emutation has been reported in 29–83% of patients
with PTC overall (56), with the smallest proportion (29%)
reported by Namba et al. (57). To be conservative, this
sample-size calculation assumes that the BRAFV600E muta-
tion will be present in 25% of study subjects overall. Based
upon the assumption that LNM will be present in 18% of
BRAFV600E-negative individuals and 38% of those who are
BRAFV600E positive (58), a sample size of 224 individuals
was required to examine the relationship between BRAFV600E
status and lymph node metastasis with 80% power at an alpha
level of 0.05 (two sided).
Statistical analysis. In order to explore the relationships
between molecular markers, BRAFV600E and miRs, and rou-
tine clinicopathologic features of PTC, a univariate analysis
was performed on patient sex, age, tumor size, multifocality,
LVI, involvement of surgical margins, ETE, CLNM, ad-
vanced AJCC stage, histological subtype, and follicular and
tall-cell component percentage. In order to find significant
molecular predictors of CLNM, a multivariable logistic re-
gression analysis was performed, adjusting for established
clinicopathologic predictors, including patient age ‡45 years,
sex, tumor size >2 cm, multifocality, LVI, involvement of
surgical margins, ETE, and follicular and tall-cell compo-
nent. Since relative levels of expression of the studied miRs
were highly correlated with each other, these analyses were
performed examining one miR at a time. In addition, multi-
variable analysis was performed examining each molecular
marker individually controlling for factors that potentially
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would have been available preoperatively, including patient
age, sex, tumor size, BRAFV600E mutation, and miR expres-
sion. To explore the possibility that variability in miR ex-
pression might be associated with the likelihood of CLNM in
patients without indication of CLN involvement, only those
patients who underwent prophylactic CLND both across the
entire cohort and within the subset of patients diagnosed with
CVPTC alone were examined. Since PTCs classified as
CVPTC may harbor up to 98% follicular and up to 49% tall-
cell components, the possibility that the follicular and tall-
cell component percentages presented an influence in the
CVPTC subgroup was also explored, and the respective
percentages were included in the CVPTC analysis. Finally,
statistical analyses for the entire cohort, including those who
underwent therapeutic CLND, were performed and are pre-
sented in the Supplementary Data (Supplementary Data are
available online at www.liebertpub.com/thy). All statistical
analyses were conducted using R v0.98.507 (http://cran.r-
project.org). A p-value of <0.05 was defined as statistically
significant.
Results
Demographics
A total of 237 patients underwent prophylactic CLND and
were included in the study. The prophylactic cohort of 237
patients included 173women (73%) and 64men (27%) with a
mean age of 47.7 – 14.5 years and a mean tumor size of
2 – 1.2 cm. Multifocality was observed in 95 (40%) cases,
involvement of surgical margins in 34 (14%) cases, LVI in 30
(13%) cases, ETE in 55 (23%) cases, and CLNM in 101
(43%) cases. One hundred and seventy (72%) tumors were
positive for the BRAFV600E mutation. In three cases (1.3%),
the results were equivocal for at least one of the molecular
analyses (BRAFV600E mutation or miR expression); these
were therefore excluded from those specific analyses. One
hundred and ninety-two cases had CVPTC (81%), 27 had
FVPTC (11%), and 18 had TCVPTC (8%; Table 1).
Predictors of CLNM in all PTC subtypes
Univariate logistic regression analyses in patients who
underwent prophylactic neck dissection demonstrated sig-
nificant positive association between the BRAFV600E muta-
tion ( p = 0.01), miR-146b-3p ( p= 0.01), miR-146b-5p ( p<
0.01), miR-221 ( p = 0.04), miR-222 ( p < 0.01), tumor size
( p < 0.01), multifocality ( p= 0.01), positive surgical margins
( p < 0.01), LVI ( p < 0.01), ETE ( p < 0.01), and advanced
AJCC stage ( p < 0.01) with CLNM. Multivariable logistic
regression analysis (Table 2), controlling for each molecular
marker, sex, age, tumor size, multifocality, LVI, positive
surgical margins, ETE, and histological subtypes, found only
miR-146b-3p ( p = 0.03), miR-146b-5p ( p = 0.02), multi-
focality ( p < 0.05), LVI ( p < 0.01), and ETE ( p < 0.01) to be
independent predictors of CLNM. The BRAFV600E mutation
( p = 0.05) was only found to have a borderline association
with CLNM in this analysis (Table 2).
In a second multivariable logistic regression analysis
limited to predictors available preoperatively only (molecu-
lar markers, age, sex, and tumor size) in prophylactic CLND
patients, the BRAFV600E mutation ( p = 0.01), miR-146b-3p
( p = 0.01), miR-146b-5p ( p = 0.01), miR-222 ( p = 0.01), and
tumor size >2 cm ( p< 0.05) were found to predict CLNM
independently (Table 3). The relative expression levels of
miR-146b-3p, miR-146b-5p, and miR-222 were associated
with a 10%, 15%, and 16% increase in the relative risk of
CLNM, respectively (Table 3 and Fig. 1). Notably, in the
prophylactic CLND cohort, patients who were BRAFV600E
positive had a 48% chance of harboring CLNM, whereas
those who were BRAFV600E negative had a 28% chance, re-
sulting in a sensitivity of 65.9%, a specificity of 46.5%, a
positive predictive value of 47.6%, and a negative predictive
value of 71.8% for the BRAFV600E mutation.
Predictors of CLNM in the CVPTC histological subtype
In univariate logistic regression analyses focusing on the
192 patients with CVPTC who underwent prophylactic neck
dissection, miR-146b-3p ( p= 0.03), miR-146b-5p ( p< 0.01),
miR-221 ( p = 0.02), miR-222 ( p < 0.01), tumor size >2 cm
( p= 0.01), multifocality ( p = 0.04), positive surgical margins
( p< 0.01), LVI ( p < 0.01), ETE ( p < 0.01), and advanced
AJCC stage ( p < 0.01) were found to be associated with
CLNM. Furthermore, miR-204 ( p = 0.02) was inversely
Table 1. Patient Characteristics
Clinicopathologic features n = 237 (%)
Male 64 (27)
Female 173 (73)
Age at diagnosis (years), mean – SD 48 – 15
Tumor size (cm), mean – SD 2 – 1.2
Lymph node metastasis
Central 101 (43)
Total number of CLN dissected 7.9 – 6.0
Positive number of CLN dissecteda 3.9 – 3.3
Extrathyroidal extension 55 (23)
Multifocality 95 (40)
Lymphovascular invasion 30 (13)
Involvement of surgical margins 34 (14)
AJCC
Stage I 147 (62)
Stage II 10 (4)
Stage III 77 (33)
Stage IV 3 (1)
Subtype
Classical 192 (81)
Follicular 27 (11)
Tall cell 18 (8)
BRAF mutation positive, n (%) 170 (72)
Classical 149 (78)
Follicular 6 (22)
Tall cell 15 (83)
microRNAs,b mean (SD)
21 -0.50 (1.97)
146b-3p -7.75 (1.97)
146b-5p -0.12 (1.71)
204 -7.91 (1.80)
221 -2.27 (1.78)
222 0.09 (1.35)
375 -6.30 (2.21)
aOnly includes those patients with positive disease.
bInverse dCt values relative to miR-16.
AJCC, American Joint Committee on Cancer; CLN, central
lymph node; SD, standard deviation.
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associated, and the BRAFV600E mutation ( p = 0.12) and fol-
licular and tall-cell component percentages were not found to
be associated with CLNM. Multivariable logistic regression
analysis of only CVPTC cases undergoing prophylactic neck
dissections (Table 4), while controlling for each molecular
marker, sex, age, size, multifocality, LVI, positive surgical
margins, ETE, and follicular and tall-cell component, found
only miR-146b-5p ( p= 0.01) and miR-222 ( p = 0.02), LVI
( p < 0.01), and ETE ( p < 0.05) to be independent predictors
of CLNM. BRAFV600E was not significantly associated with
CLNM in this subset ( p= 0.09). Multivariable logistic re-
gression analysis in all CVPTC patients, including only
predictors available preoperatively (molecular markers, age,
sex, and tumor size), found miR-146b-5p ( p = 0.01), miR-
221 ( p= 0.03), miR-222 ( p < 0.01), and size >2 cm ( p< 0.05)
to be independent predictors of CLNM. BRAFV600E was
again not associated with CLNM ( p= 0.09; Table 5).
Discussion
To the authors’ knowledge, this is the largest prospective
study to date examining the association of BRAFV600E and
miRs with aggressive clinicopathologic variables of PTC,
particularly the presence of CLNM. Due to current contro-
versies in the surgical management of PTCs and prophylactic
CLND as well as ambiguity in the literature, molecular
markers that allow for risk stratification for the presence of
CLNM would be invaluable in the clinical arena.
In the patients with no clinical indications of CLNM,
where these molecular markers would be most valuable,
miR-146b-3p, and miR-146b-5p were identified to be pre-
dictive of CLNM. Furthermore, because the clinical decision
to perform a CLND is determined preoperatively, a multi-
variable analysis among prophylactic CLND patients, con-
trolling for clinicopathologic variables that are available
preoperatively (age, sex, and tumor size), is critical for the
identification of molecular markers with clinical utility. This
subgroup analysis of individual miRs identified elevated
levels of miR-146b-3p, miR-146b-5p, and miR-222 as in-
dependent predictors of the presence of CLNM. More im-
portantly, in this group, each doubling of expression of these
markers was associated with a 10%, 15%, and 16%, increase
in the risk of CLNM, respectively. These findings are con-
sistent with previously reported studies that identified posi-
tive associations of these miRs with various features of PTC
aggressiveness (28,33,34,37,39,40,42–44,59). Three of the
miRs investigated were found to predict CLNM in the mul-
tivariate model. Inspection of the bar graphs in Figure 1,
however, clearly shows significant overlap in expression of
these miRs in the two outcome groups, raising legitimate
questions about their clinical usefulness as individual prog-
nostic markers. Each doubling of expression of these markers
was associated with increased risk of CLNM. Unfortunately,
this only segregated CLND cases at higher levels of ex-
pression that were only seen in a few cases, providing only
poor sensitivity at acceptable levels of specificity. These re-
sults speak to the concept and interpretation of statistical
significance versus actual applicability of molecular markers
clinically.
The BRAFV600Emutation was significantly associated with
CLNM in patients undergoing prophylactic central neck
dissection when specifically controlling for preoperatively
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available clinicopathologic variables in all PTC subtypes.
One explanation for this result, as exhibited in TCGA Thy-
roid Project data, is that the BRAFV600E mutation prevalence
varies across PTC subtypes (12). Thus, the incorporation of
the BRAFV600E mutation with subtypes of PTCs with low
rates of the BRAFV600E mutation (e.g., FVPTC), along with a
favorable phenotype, may confound the results to identify a
positive association between BRAFV600E and aggressive be-
havior, rather than simply being a result of subtypes having
different mutation rates. TCGA has reported that the
BRAFV600E mutation status is strongly enriched in CVPTCs,
which are more aggressive than their FVPTC counterparts
are. Indeed, when a subgroup analysis was performed only in
the CVPTCs of our cohort, the BRAFV600E mutation was no
longer an independent predictor of CLNM. This finding is
similar to a retrospective study previously performed with the
same institutions (23). These findings are attributed to the fact
that the entire cohort consisted of CVPTC as well as FVPTC
and TCVPTC, the latter two having a lower and higher BRAF
mutation rate with correspondingly lower and higher rates of
LNM. Thus, it is believed that the FVPTC and TCVPTC may
have contributed to finding a correlation in the entire series,
but not in the CVPTC-only group.
In the present study, while BRAFV600E mutation status was
identified as being statistically significantly associated with
CLNM in the analysis of all histological subtypes that un-
derwent prophylactic CLND, the ability to predict the pres-
ence of LNM with BRAFV600E analysis (48% for BRAFV600E
positive vs. 28% for BRAFV600E negative) would likely not
have any useful clinical applicability. In other words, its
positive and negative predictive value (48% and 72%, re-
spectively) limit its clinical utility as a stand-alone marker.
The TCGA molecular characterization of PTCs has re-
vealed distinct molecular signatures between the different
PTC subtypes. Furthermore, many of these molecular dif-
ferences are associated with the percent follicular component
in the tumor. Therefore, studying molecular markers while
treating PTC as a homogenous disease may lead to inaccurate
conclusions being drawn based on molecular markers and
tumor phenotypes. To that end, a subgroup analysis was
performed to consider the significance of molecular markers
in the CVPTC subtype alone, excluding FVPTCs and
TCVPTCs, but including a measure of the follicular and tall-
cell component percentages present in the CVPTCs, a vari-
able heretofore not incorporated in similar analyses. CVPTCs
represented the largest cohort (192 cases) in the study, and a
subgroup analysis, controlling for all clinicopathologic var-
iables in the prophylactic group, identified miR-146b-5p and
miR-222 to be predictive of CLNM; an analysis limited to
preoperative clinicopathologic variables only found miR-
146b-5p, miR-221, and miR-222 to be associated with
CLNM. As discussed, BRAFV600E was not significantly
Table 3. Multivariate Analysis of Individual Molecular Marker
with Preoperative Clinicopathologic Variables in Prophylactic PTCs (n = 237)
Statistic of molecular marker Clinicopathologic factors (p-value only)
Molecular marker RR CI p-Value Sex Age (‡45 years) Size (>2 cm)
BRAFV600E 1.69 1.11–2.57 0.01* 0.52 0.85 0.01*
miR-21 1.04 0.92–1.16 0.56 0.67 0.72 0.01*
miR-146-3p 1.10 1.02–1.19 0.01* 0.96 0.98 0.01*
miR-146-5p 1.15 1.04–1.26 0.01* 0.75 0.69 0.01*
miR-204 0.96 0.88–1.04 0.30 0.54 0.80 0.01*
miR-221 1.07 0.99–1.16 0.07 0.66 0.64 0.01*
miR-222 1.16 1.03–1.30 0.01* 0.47 0.76 0.01*
miR-375 1.05 0.98–1.11 0.15 0.51 0.87 <0.01*
Each row represents an independent preoperative predictor model performed for CLNM. In the prophylactic cohort, independent
preoperative predictors for CLNM were BRAFV600E mutation, miR-146b-3p, miR-146-5p, miR-222, and tumor size.
*Statistically significant.
FIG. 1. Micro RNA (miRNA) expression levels of predictive miRs in the prophylactic CLND subgroup (n = 237). Tukey
boxplots showing medians, interquartile range (IQR), and whiskers extending to 1.5 · IQR showing the inverse dCt values
of (a) miR-146-3p, (b) miR-146-5p, and (c) miR-222 relative to miR-16. Outliers are represented by circles. CLND, central
lymph node dissection; LN(+), lymph node–positive group; LN(–), lymph node–negative group.
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associated with CLNM in CVPTCs, nor was the extent of the
follicular and tall-cell components of the CVPTCs.
This prospective study examining a consecutive cohort of
patients was adequately powered to examine relationships
between potentially useful molecular markers and the preva-
lence of pathologically confirmed CLNM among patients with
no clinical indication of CLNM. Our multi-institutional study
is also the largest prospective study of patients with prophy-
lactic CLND that examines the association of BRAFV600E
and miRs with aggressive clinicopathologic variables of PTC.
Most existing studies are retrospective and include non-
consecutive, heterogeneous CLND cohorts and therapeutic
CLND cases (50). Only one previous prospective study in-
cluded patients who underwent prophylactic CLND, but was
comprised of only 148 patients and from a single institution
(18). While this prospective study overcomes major patient
selection biases arising from retrospective non-consecutive
and heterogeneous CLND cohorts that include therapeutic
CLND cases, there are some limitations that require consid-
eration. First, the study contains PTCs of various subtypes,
namely CVPTC, FVPTC, and TCVPTC, which have different
degrees of aggressiveness. The low number of patients with
FVPTC and TCVPTC did not permit an adequately powered
subgroup analysis within each disease subtype. Second, bias
may be introduced by including patients with a clear diagnosis
of PTC and excluding patients with indeterminate and suspi-
cious Bethesda cytology categories, as the latter would have
included a larger number of FVPTCs. However, in general,
surgeons would not consider prophylactic CLND unless the
diagnosis of PTC was clear preoperatively. Third, the patho-
logic spectrum of LNM based on size was not available.
Therefore, a risk-stratification analysis based on these factors
could not be performed. Lastly, variations in the exact surgical
techniques and surgical practice patterns may have introduced
undetected biases.
The TCGA experience characterized molecular pheno-
types of PTC and highlighted the importance of considering
molecular differences in treatment of the disease. It has
provided a great resource to researchers. However, unfortu-
nately, aggressive PTC cases are under-represented, and
follow-up information is incomplete at best. Therefore, there
is a need for a comprehensive characterization of the
Table 4. Multivariate Analysis of Individual Molecular Marker
with Postoperative Clinicopathologic Variables in Prophylactic CVPTC (n= 192)
Statistic of molecular marker Significance of clinicopathologic factors (p-value only)
Tall
cell % LVI ETE
Molecular
marker RR CI p-Value Sex
Age
(‡45 years)
Size
(>2 cm) Multifocality Margins
Follicular
%
BRAFV600E 1.49 0.94–2.37 0.09 0.96 0.33 0.15 0.15 0.47 0.99 0.97 <0.01* <0.01*
miR-21 0.97 0.86–1.11 0.69 0.96 0.55 0.23 0.07 0.36 0.74 0.91 <0.01* 0.01*
miR-146-3p 1.09 0.99–1.18 0.07 0.67 0.29 0.16 0.17 0.30 0.59 0.75 <0.01* 0.01*
miR-146-5p 1.15 1.03–1.29 0.01* 0.74 0.15 0.30 0.05 0.64 0.75 0.97 <0.01* 0.02*
miR-204 0.94 0.86–1.02 0.15 0.99 0.24 0.41 0.12 0.43 0.89 0.80 <0.01* 0.03*
miR-221 1.07 0.98–1.17 0.11 0.97 0.16 0.33 0.07 0.48 0.72 0.90 <0.01* 0.02*
miR-222 1.16 1.02–1.32 0.02* 0.76 0.22 0.28 0.05 0.67 0.74 0.85 <0.01* 0.02*
miR-375 1.05 0.98–1.13 0.14 0.85 0.28 0.12 0.12 0.33 0.85 0.89 <0.01* 0.03*
Formula: CLNM=molecular marker+ sex + age (‡45 years) + size (>2 cm) + FVPTC +TCVPTC +multifocality +LVI+ETE + involve-
ment of margins.
Each row represents an independent postoperative predictor model performed for CLNM. In the prophylactic CVPTC subgroup,
independent predictors for CLNM were miR-146b-5p, miR-222, LVI, and ETE.
*Statistically significant.
CVPTC, classical variant of PTC.
Table 5. Multivariate Analysis of Individual Molecular Marker
with Preoperative Clinicopathologic Variables in Prophylactic CVPTCs (n = 192)
Statistic of molecular marker Clinicopathologic factors (p-value only)
Molecular marker RR CI p-Value Sex Age (‡45 years) Size (>2 cm)
BRAFV600E 1.50 0.93–2.40 0.09 0.32 0.61 0.02*
miR-21 1.02 0.90–1.15 0.80 0.42 0.95 0.01*
miR-146-3p 1.09 1.00–1.19 0.06 0.69 0.70 0.01*
miR-146-5p 1.17 1.05–1.32 0.01* 0.56 0.41 0.02*
miR-204 0.92 0.84–1.01 0.08 0.42 0.61 0.04*
miR-221 1.10 1.01–1.19 0.03* 0.44 0.36 0.03*
miR-222 1.20 1.06–1.36 0.00* 0.28 0.50 0.02*
miR-375 1.06 0.99–1.14 0.09 0.33 0.76 <0.01*
Formula: CLNM =molecular marker+ sex+ age (>45 years) + size (>2 cm).
Each row represents an independent preoperative predictor model performed for CLNM. In the CVPTC prophylactic subgroup,
independent preoperative predictors for CLNM were miR-146-5p, miR-221, miR-222, and tumor size.
*Statistically significant.
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relationships between miRs and CLNM in studies that are
adequately powered to permit examination across benign and
aggressive PTCs with complete follow-up information, while
avoiding the selection bias introduced by selective CLND.
While the current findings suggest the potential for de-
veloping miR-related predictive tools that may have clinical
utility, this study was performed on FFPE tumor samples, and
any future applicability would need to be applied to FNA
samples. It is well known, however, that mutational analysis
of the BRAF gene is reliable in FNA samples and correlates
with corresponding tumors (48,49). Importantly, this ex-
ploratory study relied upon patient-specific relative values of
miR expression rather than absolute values. In order to
maximize the clinical usefulness of miR expression as a de-
cision tool for determining the need for CLND, developing
and validating techniques for measuring absolute levels of
target miRs may be required. Along with others, this study
has shown the ability to identify molecular alterations in
PTCs, both at the DNA level and in terms of gene expression,
from these sample types (23), and further consideration
should be made to investigate their clinical utility.
Conclusions
In patients undergoing prophylactic CLNDs, miR-146b-
3p, miR-146b-5p, and miR-222 were identified as potential
markers of CLNM. BRAFV600E mutation was significantly
associated with CLNM among patients with all PTC subtypes
examined as a single group. When present, the BRAFV600E
mutation was associated with a 48% chance of node posi-
tivity, while BRAFV600E negative patients had a 28% chance
of node positivity. This proportional difference in the BRAF-
associated likelihood of CLNM may not be useful clinically
when deciding whether a patient should undergo prophylactic
CLND. Furthermore, this statistical significance is likely due
to the BRAFV600E mutation prevalence in the different PTC
subtypes (FVPTC and TCVPTC). The results also demon-
strate, however, that statistical significance does not neces-
sarily equal clinical usefulness (48% vs. 28% LNM). The
usefulness of BRAFV600E and other markers will depend
strongly on the context and pretest probability of a positive
test result. In cases with a high likelihood of BRAFV600E
positivity, such as patients diagnosed with PTC on FNA,
BRAFV600E testing is unlikely to be helpful. In more ambig-
uous cases, for example patients with indeterminate and
suspicious Bethesda categories, the presence of a BRAFV600E
mutation may increase the likelihood of being associated
with LNM, but this has to be balanced with the lower overall
risk of associated LNM in these categories. Before consid-
eration can be given to creating a clinically useful prognostic
prediction model for CLNM for patients with PTC, sub-
stantial additional work will be required to understand the
observed relationships, paying particular attention to pa-
rameters that impact pretest probabilities, such as therapeutic
versus prophylactic CLND intent, or the histological subtype
composition of a given study cohort.
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